So that’s our confidence on this. You asked about the, call it, the sequence of the quarters if you were plotting out, we’ve been quite upfront and we expect mid-20s. I would say the growth rate is higher in the fourth quarter than this in the third as we cycle through some of the negative vectors, and then we implement the positive ones. But we’re pretty comfortable with the overall profile. Capital allocation, our priority right now is debt and probably tuck-on acquisitions, they would be small in size and only focused on the healthcare business. And then you had a question on Boots, which, do you want to take that one on Boots?
Rosalind Brewer : Sure. So on the Boots business, we’ve been pleased with their performance as Jim talked about in comparison to U.S. business, our healthcare business. What we feel like is we’ve got a balanced business here in terms of what we’re seeing in Boots and they are continuing to take market share. And it’s a business that is nice to have. It’s been complementary. And until further notice, it’s a good business for us to have.
James Kehoe : Yes. And you would have seen them, Erin, in the quarter that we did dispose just after the quarter, we disposed of a fairly large portion of Option Care. And we’ve taken our stake below 10%. I think it’s 6% something. So we’re not — we’re still making progress against all of the portfolio simplification goals. We’ve taken action like on parts of ABC. Option Care is now down to 6% range. So we’re carefully assessing when the right moment is on all of these vehicles on simplification of the company to ensure that we have the firepower to drive and create a successful healthcare services business. That’s the goal, and that’s the strategy Roz laid out and we’re resolute in driving against this strategy.
Operator: And we have reached the end of our question-and-answer session. Ms. Roz Brewer, I turn the call back over to you for some final closing remarks.
Rosalind Brewer : Thanks. So thanks, everyone, for joining us. Let me sum up what you heard today, particularly in the Q&A portion. So just in short, the U.S., we’ve really achieved a balanced performance. Our core retail sales are up mid-single digits, better-than-expected sequential improvement in our comp scripts. And then internationally, Boots has delivered eight consecutive quarters with strong comp performance which accelerated to 16% this quarter. So we feel really good about leaving this quarter. So when we talk about what are we thinking about recession, inflation? Our business is not only strong, but is showing resiliency. We’ve been able to absorb various industry-wide shocks such as rising labor costs and the inflationary pressures.
So at the same time, though, we’re moving beyond our peak investment period in health care, and we’ve turned the corner on comping last year’s COVID demand. So that’s what we’re referencing in terms of an inflection point. I’m really happy about this team. We’re clearly executing against our plans and is showing up in the results. We’ve achieved a really solid first half performance and broadly in line with our expectations. The investments that you all have been tracking very carefully, they’re accelerating, and they’re building out our healthcare growth engine as we designed and planned. And then the portfolio simplification is working, and it’s unlocking the value that we need and funding our transformation. So I would just reiterate that we’re maintaining guidance and pivoting to a strong second half of the year.
And I appreciate your time on the call. Thank you. Have a great rest of the day.
Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.
